| Literature DB >> 29425031 |
Tianlin Guo1, Philipp Dätwyler2, Ekaterina Demina3, Michele R Richards1, Peng Ge1, Chunxia Zou1, Ruixiang Zheng1, Anne Fougerat3, Alexey V Pshezhetsky3, Beat Ernst2, Christopher W Cairo1.
Abstract
Human neuraminidases (NEU) are associated with human diseases including cancer, atherosclerosis, and diabetes. To obtain small molecule inhibitors as research tools for the study of their biological functions, we designed a library of 2-deoxy-2,3-didehydro- N-acetylneuraminic acid (DANA) analogues with modifications at C4 and C9 positions. This library allowed us to discover selective inhibitors targeting the human NEU3 isoenzyme. Our most selective inhibitor for NEU3 has a Ki of 320 ± 40 nM and a 15-fold selectivity over other human neuraminidase isoenzymes. This inhibitor blocks glycolipid processing by NEU3 in vitro. To improve their pharmacokinetic properties, various esters of the best inhibitors were synthesized and evaluated. Finally, we confirmed that our best compounds exhibited selective inhibition of NEU orthologues from murine brain.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29425031 DOI: 10.1021/acs.jmedchem.7b01574
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446